136 related articles for article (PubMed ID: 34061432)
1. Secondary histiocytic sarcoma with BRAF
Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
Pediatr Blood Cancer; 2021 Oct; 68(10):e29166. PubMed ID: 34061432
[No Abstract] [Full Text] [Related]
2. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
[No Abstract] [Full Text] [Related]
3. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
[No Abstract] [Full Text] [Related]
4. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
5. Histiocytic sarcoma arising from thyroid gland with BRAF V600E mutation.
Ge R; Chang Y; Gan Y; Zhu H; Liu C
Pathology; 2020 Aug; 52(5):603-605. PubMed ID: 32600657
[No Abstract] [Full Text] [Related]
6. Secondary histiocytic sarcoma with BRAF
Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
Pediatr Blood Cancer; 2020 May; 67(5):e28200. PubMed ID: 32037654
[No Abstract] [Full Text] [Related]
7. Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.
Hu B; Patel JL; Tao R; Cannon RB; Monroe M; Goyal G
J Natl Compr Canc Netw; 2022 Mar; 20(6):618-621. PubMed ID: 35325867
[TBL] [Abstract][Full Text] [Related]
8. Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Ann Hematol; 2020 Mar; 99(3):649-651. PubMed ID: 32009180
[No Abstract] [Full Text] [Related]
9. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
[TBL] [Abstract][Full Text] [Related]
10. BRAF
Vaughn JL; Freitag CE; Hemminger JA; Jones JA
J Med Case Rep; 2017 Apr; 11(1):92. PubMed ID: 28376906
[TBL] [Abstract][Full Text] [Related]
11. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.
Go H; Jeon YK; Huh J; Choi SJ; Choi YD; Cha HJ; Kim HJ; Park G; Min S; Kim JE
Histopathology; 2014 Aug; 65(2):261-72. PubMed ID: 24720374
[TBL] [Abstract][Full Text] [Related]
12. Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs).
Kakkar A; Majumdar A; Kumar A; Tripathi M; Pathak P; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
Epilepsy Res; 2016 Nov; 127():141-151. PubMed ID: 27599148
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in histiocytic sarcoma identified by next generation sequencing.
Liu Q; Tomaszewicz K; Hutchinson L; Hornick JL; Woda B; Yu H
Virchows Arch; 2016 Aug; 469(2):233-41. PubMed ID: 27259537
[TBL] [Abstract][Full Text] [Related]
15. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W; Rosenwald A; Geissinger E; von Kalle C; Jäger D; Brors B; Weichert W; Grüllich C; Glimm H; Brummer T; Fröhling S
Leukemia; 2016 Apr; 30(4):937-46. PubMed ID: 26582644
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
[TBL] [Abstract][Full Text] [Related]
17. A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review.
Zhang L; Zhang G; Zheng H; Jiang B; Ju Y; Duan Q; An L; Shi H
Brain Tumor Pathol; 2024 Jan; 41(1):18-29. PubMed ID: 38100030
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of BRAF and mTOR in
Sen S; Tanaka R; Khatua S; Zaky W; Janku F; Penas-Prado M; Weathers SP; Behrang A; Roszik J; Subbiah V
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843426
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
20. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
